诺和诺德一季度销售额781亿丹麦克朗,同比增长19%,但不及预期的787亿丹麦克朗。尽管Ozempic表现强劲,但其他GLP-1药物和Wegovy的销售额未达预期。公司下调了其以不变汇率计算的全年销售额预测。原先预计销售额增长16%到24%,但现在调整为13%到21%。同时,公司将运营利润预期从之前的19%到27%下调至16%到24%。5月7日,诺和诺德公布一季度财报:主要财务数据:2025年Q1...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.